In-/off-label use of biologic therapy in systemic lupus erythematosus

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Gatto, Mariele ^a   Kiss, Emese ^b,c   Naparstek, Yaakov ^d   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anti B cell therapies; Belimumab; Biologic therapy; Randomized controlled trials; Systemic lupus erythematosus

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84894040830     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-30     Document Type: Note

References (38)

1. Stohl W. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2013, 9:705-720. 10.1038/nrrheum.2013.136, 24018550.
2. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severe active systemic lupus erythematosus. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
3. Furie R. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind, phase III LUNAR study. Arthritis Rheum 2009, 60:16-21.
4. Postal M, Costallat LT, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol 2012, 2012:578641. 3303577, 22500177.
5. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014, 73:183-190. 10.1136/annrheumdis-2012-202760, 3888603, 23313811.
6. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012, 14:R33. 10.1186/ar3738, 3392829, 22325903.
7. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD2 antibody) for immune therapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R74. 10.1186/ar1942, 1526638, 16630358.
8. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731. 10.1016/S0140-6736(10)61354-2, 21296403, BLISS-52 Study Group.
9. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930. 10.1002/art.30613, 22127708, BLISS-76 Study Group.
10. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087. 10.1002/art.27601, 20533545.
11. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258. 10.1002/art.10681, 12483729, IDEC-131 Lupus Study Group.
12. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004, 13:391-397. 10.1191/0961203304lu1032oa, 15230298.
13. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:326-337. 10.1038/nrrheum.2010.68, 20520647.
14. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010, 22:504-509. 10.1097/BOR.0b013e32833b475e, 20502332.
15. Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013, 15:S2. 10.1186/ar3910, 3891482, 24267197.
16. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur Immunol 2000, 30:2038-2047.
17. Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009, 18:690-697. 10.1177/0961203309102557, 19502264.
18. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552. 10.1002/art.27221, 3057537, 20112381.
19. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B, Lupus Interferon Skin Activity (LISA) Study Investigators Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody in systemic lupus erythematosus: a phase I, multicentre, double-blind randomized study. Ann Rheum Dis 2011, 70:1905-1913. 10.1136/ard.2010.144485, 21798883, Lupus Interferon Skin Activity (LISA) Study Investigators.
20. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. Arthritis Rheum 2010, 62:2458-2466. 10.1002/art.27541, 20506527.
21. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martínez-Berriotxoa A, García-Hernández F, Callejas-Rubio JL, Rascón J, D'Cruz D, Jayne D, Ruiz-Irastorza G, Emery P, Isenberg D, Ramos-Casals M, Khamashta MA, UK-BIOGEAS Registry Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364. 10.1016/j.autrev.2011.10.009, 22032879, UK-BIOGEAS Registry.
22. Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010, 28:468-476. BIOGEAS Study Group.
23. Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013, 28:106-111. 10.1093/ndt/gfs285, 22764193.
24. Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013, 72:1280-1286. 10.1136/annrheumdis-2012-202844, 23740227.
25. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71:1771-1782. 10.1136/annrheumdis-2012-201940, 3465859, 22851469.
26. Dörner T, Goldenberg DM. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag 2007, 3:953-959. 2376077, 18473018.
27. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, Isenberg DA, Kelley L, Kilgallen B, Barry AN, Wegener WA, Goldenberg DM. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 2013, 52:1313-1322. 10.1093/rheumatology/ket129, 23542611.
28. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009, 119:1066-1073. 10.1172/JCI38010, 2673851, 19411764.
29. Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 2012, 125:327-336. 10.1016/j.amjmed.2011.09.010, 22444096.
30. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 66:2913-2916.
31. Mok CC. Abatacept for systemic lupus erythematosus: the outlook. Expert Opin Biol Ther 2012, 12:1559-1561. 10.1517/14712598.2012.721773, 22946545.
32. Zampieri S, Alaibac M, Iaccarino L, Rondinone R, Ghirardello A, Sarzi-Puttini P, Peserico A, Doria A. Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus. Ann Rheum Dis 2006, 65:545-548. 10.1136/ard.2005.039362, 1798098, 16096331.
33. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE - promising or crazy?. Autoimmun Rev 2012, 11:321-325. 10.1016/j.autrev.2011.05.001, 21619949.
34. Matsumura R, Umemiya K, Sugiyama T, Sueishi M, Umibe T, Ichikawa K, Yoshimura M, Study Group on Nephrology at the National Hospital Organization of Japan Anti-tumor necrosis factor therapy in patients with difficult-to-treat nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009, 27:416-421. Study Group on Nephrology at the National Hospital Organization of Japan.
35. Gatto M, Zen M, Ghirardello A, Bettio S, Bassi N, Iaccarino L, Punzi L, Doria A. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013, 12:523-536. 10.1016/j.autrev.2012.09.003, 23000207.
36. van Vollenhoven RF. Challenges and opportunities in SLE clinical trials. Curr Opin Rheumatol 2013, 25:606-615. 10.1097/BOR.0b013e328363f4f2, 23917158.
37. Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014, Jan 27 [Epub ahead of print].
38. Zen M, Bassi N, Nalotto L, Canova M, Bettio S, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012, 30:856-863.